FDA wants cleft birth defect analysis for Vivus weight-loss drug
This article was originally published in Scrip
Executive Summary
Investors chose to see the glass as half empty 21 January after Vivus revealed that the US FDA wants an analysis of birth defects associated with one of the two active ingredients in the company's experimental weight-loss drug Qnexa (phentermine/topiramate).